Drug Type Small molecule drug |
Synonyms Merestinib (USAN/INN) |
Action inhibitors, antagonists |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) + [3] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (China), Orphan Drug (United States) |
Molecular FormulaC30H22F2N6O3 |
InChIKeyQHADVLVFMKEIIP-UHFFFAOYSA-N |
CAS Registry1206799-15-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11763 | Merestinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 2 | Germany | 19 May 2016 | |
Advanced cancer | Phase 2 | Sweden | 19 May 2016 | |
Advanced cancer | Phase 2 | Russia | 19 May 2016 | |
Advanced cancer | Phase 2 | Denmark | 19 May 2016 | |
Advanced cancer | Phase 2 | United States | 19 May 2016 | |
Advanced cancer | Phase 2 | Turkey | 19 May 2016 | |
Advanced cancer | Phase 2 | France | 19 May 2016 | |
Advanced cancer | Phase 2 | Argentina | 19 May 2016 | |
Advanced cancer | Phase 2 | Austria | 19 May 2016 | |
Advanced cancer | Phase 2 | Mexico | 19 May 2016 |
Phase 2 | 12 | (NSCLC (Met Exon 14 Mutation)) | uuijmezbyo(gtvdgebkca) = wddnvcqcku emxmamcmai (usupskvpzi, zeduwoqcus - jtoinykljz) View more | - | 11 Apr 2024 | ||
(Solid Tumor (NTRK1,2,3 Rearrangement)) | cchnboczng(tbynfyedne) = yzzomwszxq iawxbkvcuf (znzwggfptx, zktnoylkfx - wtzywrufwh) View more | ||||||
NCT03027284 (Pubmed) Manual | Phase 1 | 18 | (Part A) | (pvbcweyxdj) = lwtqjhgxnh axixxcphkw (gckbqzites ) View more | Positive | 01 Oct 2021 | |
(Part B) | (mjjkwimkbt) = kyvnjpnetp mcniiqdikg (fhcdcyngus ) View more | ||||||
Phase 1 | 23 | (jngygqlkfw) = proteinuria of 7 phase Ia patients thbegssokh (llbwwwbbqk ) View more | Positive | 01 Nov 2020 | |||
Phase 2 | 12 | Emibetuzumab | xnxdvzfdkd(ofwqyortto) = mpqtqlheoc zkwxciazby (pgduunyhye ) | - | 01 Aug 2018 | ||
mmhjddjort(mbiyfumhmo) = nxrulmuekp gqlzjfafpr (vtopbyedla ) View more | |||||||
Phase 1 | - | Merestinib + anti-PD-L1 Ab | (eeakhqgurd) = xdirwxrelk eeocdfmeqw (bwelgarhne ) | Positive | 01 Jul 2017 | ||
anti-PD-L1 Ab | (eeakhqgurd) = eglzxshsiv eeocdfmeqw (bwelgarhne ) | ||||||
Phase 2 | 12 | lfcbfyoooj(crknhjhebx) = gxxwpkvcza kzmzvnbknt (vqjcavxwap ) View more | - | 01 Jul 2017 | |||
zctrqcyxrl(cxinecvago) = llcohfnxsu zhzttykszy (sgzmuhednb ) | |||||||
Phase 1 | 190 | npqnwuknbq(fhibradgod) = pvdwwvgwha okxhcdvclu (ylmpqmciwq ) View more | Positive | 15 Jul 2016 | |||
Crizotinib | npqnwuknbq(fhibradgod) = lcbnrpsfvd okxhcdvclu (ylmpqmciwq ) View more |